フィルター
4 件の結果が “7045” で取得されました
並べ替える:
アルファベット順（A-Z）
ベストセラー
B6-hTGFBI
製品ID :
C001546
系統:
C57BL/6JCya
状況:
説明:
Corneal dystrophy (CD) refers to a group of primary hereditary progressive corneal diseases. The typical clinical presentation involves gradual loss of corneal transparency in both eyes, often leading to recurrent corneal erosions and visual impairment. The TGFBI gene (also known as BIGH3) encodes an extracellular matrix protein called keratoepithelin (KE protein), which plays a role in cell growth, differentiation, wound healing, cell adhesion, migration, apoptosis, proliferation, and tumorigenesis [1]. Mutations in the TGFBI gene are associated with various types of corneal dystrophy. Abnormal accumulation of mutated TGFBI deposits in the corneal epithelium and stroma progressively affects corneal transparency, leading to visual impairment.
Currently, therapeutic pipelines targeting the TGFBI gene have entered preclinical research stages. For instance, SiSaf Ltd. is developing a siRNA drug pipeline called SIS-201-CD, which aims to treat the disease by specifically inhibiting abnormal TGFBI expression. Most gene therapies target human genes, but considering the genetic differences between animals and humans, humanizing mouse genes can accelerate the development of TGFBI-targeted gene therapies for clinical use. This strain is a mouse Tgfbi gene humanized model and can be used for research on CD. The homozygous B6-hTGFBI mice are viable and fertile. In addition, based on the independently developed TurboKnockout fusion BAC recombination technology, Cyagen can also generate hot mutation models based on this strain and provide customized services for specific mutations to meet the experimental needs in pharmacology and other fields related to CD.
Corneal dystrophy (CD) refers to a group of primary hereditary progressive corneal diseases. The typical clinical presentation involves gradual loss of corneal transparency in both eyes, often leading to recurrent corneal erosions and visual impairment. The TGFBI gene (also known as BIGH3) encodes an extracellular matrix protein called keratoepithelin (KE protein), which plays a role in cell growth, differentiation, wound healing, cell adhesion, migration, apoptosis, proliferation, and tumorigenesis [1]. Mutations in the TGFBI gene are associated with various types of corneal dystrophy. Abnormal accumulation of mutated TGFBI deposits in the corneal epithelium and stroma progressively affects corneal transparency, leading to visual impairment.
Currently, therapeutic pipelines targeting the TGFBI gene have entered preclinical research stages. For instance, SiSaf Ltd. is developing a siRNA drug pipeline called SIS-201-CD, which aims to treat the disease by specifically inhibiting abnormal TGFBI expression. Most gene therapies target human genes, but considering the genetic differences between animals and humans, humanizing mouse genes can accelerate the development of TGFBI-targeted gene therapies for clinical use. This strain is a mouse Tgfbi gene humanized model and can be used for research on CD. The homozygous B6-hTGFBI mice are viable and fertile. In addition, based on the independently developed TurboKnockout fusion BAC recombination technology, Cyagen can also generate hot mutation models based on this strain and provide customized services for specific mutations to meet the experimental needs in pharmacology and other fields related to CD.
huTGFBI-R124H
製品ID :
C002005
系統:
C57BL/6JCya
状況:
説明:
Corneal dystrophy (CD) refers to a group of primary hereditary progressive corneal diseases. The typical clinical presentation involves gradual loss of corneal transparency in both eyes, often leading to recurrent corneal erosions and visual impairment. The TGFBI gene (also known as BIGH3) encodes an extracellular matrix protein called keratoepithelin (KE protein), which plays a role in cell growth, differentiation, wound healing, cell adhesion, migration, apoptosis, proliferation, and tumorigenesis [1]. Mutations in the TGFBI gene are associated with various types of corneal dystrophy. Abnormal accumulation of mutated TGFBI deposits in the corneal epithelium and stroma progressively affects corneal transparency, leading to visual impairment.
The R124H mutation represents one of the most clinically significant genetic alterations within the TGFBI gene, specifically resulting from a missense mutation. This particular mutation is the definitive genetic cause of Granular Corneal Dystrophy type 2 (GCD2), also historically referred to as Avellino corneal dystrophy [2]. Unlike other variants that may produce a single type of protein deposit, the R124H mutation is characterized by a "mixed" pathology, leading to the simultaneous accumulation of both crumb-like granular deposits and proteinaceous lattice-like amyloid fibrils within the corneal stroma. Furthermore, the R124H mutation is notoriously sensitive to external trauma, meaning that refractive surgeries like LASIK or PRK can trigger a massive, accelerated inflammatory response and a surge in protein deposition, which often necessitates corneal transplantation to restore sight [3]. Thus, developing gene therapy is crucial for this patient population.
huTGFBI-R124H mice are generated by introducing the R124H mutation into the human TGFBI gene and subsequently knocking out exon 13 in huTGFBI mice (Catalog Number: C001546) using gene editing technology. This strain can be used for studying the pathological mechanisms and treatments of Granular Corneal Dystrophy type 2 (GCD2), as well as for the development of TGFBI-targeted drugs.
Corneal dystrophy (CD) refers to a group of primary hereditary progressive corneal diseases. The typical clinical presentation involves gradual loss of corneal transparency in both eyes, often leading to recurrent corneal erosions and visual impairment. The TGFBI gene (also known as BIGH3) encodes an extracellular matrix protein called keratoepithelin (KE protein), which plays a role in cell growth, differentiation, wound healing, cell adhesion, migration, apoptosis, proliferation, and tumorigenesis [1]. Mutations in the TGFBI gene are associated with various types of corneal dystrophy. Abnormal accumulation of mutated TGFBI deposits in the corneal epithelium and stroma progressively affects corneal transparency, leading to visual impairment.
The R124H mutation represents one of the most clinically significant genetic alterations within the TGFBI gene, specifically resulting from a missense mutation. This particular mutation is the definitive genetic cause of Granular Corneal Dystrophy type 2 (GCD2), also historically referred to as Avellino corneal dystrophy [2]. Unlike other variants that may produce a single type of protein deposit, the R124H mutation is characterized by a "mixed" pathology, leading to the simultaneous accumulation of both crumb-like granular deposits and proteinaceous lattice-like amyloid fibrils within the corneal stroma. Furthermore, the R124H mutation is notoriously sensitive to external trauma, meaning that refractive surgeries like LASIK or PRK can trigger a massive, accelerated inflammatory response and a surge in protein deposition, which often necessitates corneal transplantation to restore sight [3]. Thus, developing gene therapy is crucial for this patient population.
huTGFBI-R124H mice are generated by introducing the R124H mutation into the human TGFBI gene and subsequently knocking out exon 13 in huTGFBI mice (Catalog Number: C001546) using gene editing technology. This strain can be used for studying the pathological mechanisms and treatments of Granular Corneal Dystrophy type 2 (GCD2), as well as for the development of TGFBI-targeted drugs.
Impdh2-KO
製品ID :
S-KO-07045
系統:
C57BL/6JCya
状況:
説明:
Impdh2 is located on chromosome 9 of mice. Nuclease Technology will be used to design sgRNA; Impdh2 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Impdh2 is located on chromosome 9 of mice. Nuclease Technology will be used to design sgRNA; Impdh2 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Cxcr1-flox
製品ID :
S-CKO-07045
系統:
C57BL/6JCya
状況:
説明:
Cxcr1 is located on chromosome 1 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Cxcr1 conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Cxcr1 is located on chromosome 1 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Cxcr1 conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Items: 1 to 4 of 4
1